{"id":"W4293109639","doi":"10.1038/s41467-022-32591-8","title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Université Laval; Juravinski Cancer Centre; University of British Columbia; CancerCare Manitoba; Nova Scotia Cancer Centre; University of Ottawa; Dalhousie University; Bausch Health (Canada); Ottawa Hospital; Moncton Hospital; Centre Hospitalier de l’Université de Montréal; University of Toronto; Université de Sherbrooke; Université de Montréal; Cancer Care Ontario; Pancreas Centre (Canada); McGill University; BC Cancer Agency; Vancouver General Hospital; University of Calgary; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; Jewish General Hospital","funders":"Terry Fox Research Institute","keywords":"Gemcitabine; Durvalumab; Nab-paclitaxel; Tremelimumab; Medicine; Pancreatic ductal adenocarcinoma; Oncology; Paclitaxel; Internal medicine; Adenocarcinoma; Cancer research; Pancreatic cancer; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009421746,0.0006828022,0.001803304,0.0003658435,0.0003504342,0.0007701783,0.0006159137,0.0009716387,0.002725664],"category_scores_gemma":[0.00116893,0.000300937,0.0009150081,0.0004528651,0.0005303748,0.000444345,0.0002629854,0.002635856,0.0006196432],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009280656,"about_ca_system_score_gemma":0.001587638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00243325,"about_ca_topic_score_gemma":0.01210472,"domain_scores_codex":[0.9994015,0.0003747944,0.00002461657,0.00005679112,0.00006312704,0.00007911993],"domain_scores_gemma":[0.9994226,0.0001508331,0.0001239179,0.00004406721,0.00004575684,0.0002129132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7774869,0.01946747,0.007500268,0.001877655,0.002528846,0.0003680345,0.0001682326,0.002389614,0.0383724,0.0006666831,0.01443487,0.1347389],"study_design_scores_gemma":[0.7666224,0.2057009,0.01312461,0.0001264979,0.001259979,0.0005226287,0.00005622706,0.001545062,0.003800467,0.0002291857,0.00697725,0.00003473844],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845061,0.005206432,0.0004067341,0.001025759,0.0002637847,0.001581463,0.00139998,0.0001083671,0.005501299],"genre_scores_gemma":[0.9810125,0.003817999,0.002359118,0.001451538,0.0003714235,0.002174218,0.004462748,0.00005640769,0.004294061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002725664,"threshold_uncertainty_score":0.009118259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06866649903967512,"score_gpt":0.4222206252968865,"score_spread":0.3535541262572114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}